Researchers Develop AI Model to Make Cancer Treatment Less Toxic
By MedImaging International staff writers Posted on 20 Aug 2018 |
Image: Researchers aim to improve the quality of life for patients suffering from glioblastoma with a machine-learning model that makes chemotherapy and radiotherapy dosing regimens less toxic but still as effective as human-designed regimens (Photo courtesy of MIT).
Researchers from the Massachusetts Institute of Technology (Cambridge, MA, USA) have developed an artificial intelligence model that “learns” from patient data to make cancer-dosing regimens less toxic but still effective.
In a paper presented at the 2018 Machine Learning for Healthcare conference at Stanford University, MIT Media Lab researchers have detailed a novel machine-learning technique to improve the quality of life for patients by reducing toxic chemotherapy and radiotherapy dosing for glioblastoma, the most aggressive form of brain cancer. The “self-learning” machine-learning technique looks at the current treatment regimens in use and iteratively adjusts the doses, eventually finding an optimal treatment plan, with the lowest possible potency and frequency of doses that should still reduce tumor sizes to a degree comparable to that of traditional regimens.
In simulated trials of 50 patients, the machine-learning model designed treatment cycles that reduced the potency to a quarter or half of nearly all the doses while maintaining the same tumor-shrinking potential. It skipped doses altogether several times and scheduled administrations only twice a year instead of monthly.
The model is a major improvement over the conventional “eye-balling” method of administering doses, observing how patients respond, and adjusting accordingly, according to Nicholas J. Schork, a professor and director of human biology at the J. Craig Venter Institute, and an expert in clinical trial design. “[Humans don’t] have the in-depth perception that a machine looking at tons of data has, so the human process is slow, tedious, and inexact,” he said. “Here, you’re just letting a computer look for patterns in the data, which would take forever for a human to sift through, and use those patterns to find optimal doses.”
According to Schork, the work could be of particular interest to the US FDA, which is currently looking for ways to leverage data and artificial intelligence to develop health technologies. Regulations still need be established, he said, “but I don’t doubt, in a short amount of time, the FDA will figure out how to vet these [technologies] appropriately, so they can be used in everyday clinical programs.”
Related Links:
Massachusetts Institute of Technology
In a paper presented at the 2018 Machine Learning for Healthcare conference at Stanford University, MIT Media Lab researchers have detailed a novel machine-learning technique to improve the quality of life for patients by reducing toxic chemotherapy and radiotherapy dosing for glioblastoma, the most aggressive form of brain cancer. The “self-learning” machine-learning technique looks at the current treatment regimens in use and iteratively adjusts the doses, eventually finding an optimal treatment plan, with the lowest possible potency and frequency of doses that should still reduce tumor sizes to a degree comparable to that of traditional regimens.
In simulated trials of 50 patients, the machine-learning model designed treatment cycles that reduced the potency to a quarter or half of nearly all the doses while maintaining the same tumor-shrinking potential. It skipped doses altogether several times and scheduled administrations only twice a year instead of monthly.
The model is a major improvement over the conventional “eye-balling” method of administering doses, observing how patients respond, and adjusting accordingly, according to Nicholas J. Schork, a professor and director of human biology at the J. Craig Venter Institute, and an expert in clinical trial design. “[Humans don’t] have the in-depth perception that a machine looking at tons of data has, so the human process is slow, tedious, and inexact,” he said. “Here, you’re just letting a computer look for patterns in the data, which would take forever for a human to sift through, and use those patterns to find optimal doses.”
According to Schork, the work could be of particular interest to the US FDA, which is currently looking for ways to leverage data and artificial intelligence to develop health technologies. Regulations still need be established, he said, “but I don’t doubt, in a short amount of time, the FDA will figure out how to vet these [technologies] appropriately, so they can be used in everyday clinical programs.”
Related Links:
Massachusetts Institute of Technology
Latest Industry News News
- Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures